Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AlphaRx Receives SFDA Approval for Topical Arthritis Product

publication date: Dec 7, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AlphaRx received approval from the State FDA of China for Indaflex™, a topical arthritis relief product. Indaflex™ is a topical formulation of Indomethacin that is incorporated in a nanotechnology drug delivery system developed by AlphaRx. Previously, Indaflex™ was approved in Mexico. AlphaRx International Holdings (AIH), the Hong Kong affiliate of AlphaRx, will launch Indaflex™ in 2008, and it is already building a plant in China to produce the drug. More details....

Stock Symbols: (OTCBB:ALRX) (NYSE: MRK)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...